Kevetrin cohort update will bump things a dime or so. I don't think even a DLT announcement would do much more than that (in the opposite direction) at this point. If someone would tell us what Kevetrin is doing for patients, however, this thing could take off.
Otherwise we wait for the "pivotal" B P2B results early next year.
All other trial announcements won't do much, in my opinion, unless there are some surprises.
I think there is a pretty good chance we'll be in this range 4 or 5 months from now. Not selling, though.
Market Data 
Markets 
AI
